ArticleMolecular biology reports2026
The macrophage DAG/PKCα/ROS axis exacerbates sepsis by inducing endothelial dysfunction through activation of the p38 MAPK pathway.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aimed to investigate the role and mechanism of macrophage DAG/PKCα/ROS axis in sepsis‑induced endothelial injury.
methodsIn vitro, RAW264.7 macrophages were polarized to the M1 phenotype using lipopolysaccharide/interferon‑γ and treated with Go6976 (PKCα inhibitor). The following parameters were assessed: DAG and ROS levels, PKCα phosphorylation, M1/M2 phenotype markers and inflammatory cytokine levels. In a Transwell system, pulmonary microvascular endothelial cells were co-cultured with macrophages to evaluate endothelial cellular viability, apoptosis, inflammatory cytokine levels, barrier function, the expressions of tight junction proteins and adhesion junction proteins, and p38 MAPK phosphorylation. In vivo, mouse sepsis models were established by cecal ligation and puncture (CLP) surgery and treated with Go6976 and the p38 MAPK agonist, anisomycin. The 24 h survival rate was recorded, macrophage depletion was verified, inflammatory cytokine levels were measured, and histopathology of lung, liver and kidney was assessed. Additionally, peritoneal macrophages were isolated from mice and examined for DAG and ROS levels, inflammatory cytokine levels, M1/M2 phenotype markers, the expressions of tight junction proteins and adhesion junction proteins, and p38 MAPK phosphorylation.
resultsLipopolysaccharide/interferon‑γ activated the macrophage DAG/PKCα/ROS axis, promoted M1 polarization and inflammation, which was reversed by Go6976. LPS impaired endothelial viability, apoptosis and barrier function, which were alleviated by Go6976. In vivo, macrophage depletion or transfer of Go6976‑pretreated macrophages improved survival, reduced inflammation/organ injury, and restored junctional proteins in CLP‑induced septic mice, these effects were abolished by anisomycin.
conclusionsThe macrophage DAG/PKCα/ROS axis exacerbates sepsis by inducing endothelial dysfunction through activation of the p38 MAPK pathway.
Indexed as
Identifiers
41989633What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.